StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

Equities researchers at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 10.5 %

AKTX opened at $2.64 on Wednesday. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.40. The company has a 50 day simple moving average of $3.36 and a two-hundred day simple moving average of $2.67.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.